Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study aims to predict and prevent dangerous drug reactions

NCT ID NCT06822959

Knowledge-focused Sponsor: Direzione centrale salute, politiche sociali e disabilità Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether combining genetic tests, regular drug level checks, and careful medication reviews can help doctors prescribe the right drugs and avoid harmful side effects. It involves 450 adults with cancer and children with chronic inflammatory diseases. The goal is to create a safer, more personalized way to manage medications that could be used across the country.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 450 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2022

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients who are candidates for therapy with: Abemaciclib, Palbociclib, Ribociclib, Letrozole, Tamoxifen, Olaparib, Infliximab, Cyclophosphamide, Methotrexate, Irinotecan, Capecitabine, 5-Fluorouracil, Noraparib, Adalimumab, Imatinib, Regorafenib, Lenvatinib, Sorafenib, Sunitinib, Rucaparib, 6-MP/ Azathioprine

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Patients who are candidates for therapy with: * Abemaciclib, * Palbociclib, * Ribociclib, * Letrozole, * Tamoxifen, * Olaparib, * Niraparib, * Rucaparib, * Imatinib, * Sunitinib, * Sorafenib, * Regorafenib, * Lenvatinib, * Irinotecan, * Capecitabine, * 5-Fluorouracil, * Infliximab, * Cyclophosphamide, * Methotrexate, * Adalimumab, * 6-Mercaptopurine/Azathioprine

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Adverse drug reaction (ADR) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer Drug-Related Side Effects and Adverse Reactions

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Adverse drug reaction (ADR)

Contacts and locations

Locations

  • Centro di Riferimento Oncologico di Aviano (CRO)

    Aviano, Pordenone, 33081, Italy

  • IRCCS materno infantile Burlo Garofolo di Trieste

    Trieste, Trieste, 34137, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.